🕚 Thursday, October 30 | 10am ET / 3pm CET
The EU Medical Device Regulation (MDR) already sets strict requirements for safety, performance, and clinical evidence. Now, with the EU AI Act entering the stage, manufacturers face a new layer of obligations around transparency, risk management, and ethical use of AI in medical technologies.
In this live webinar, experts from DQS and RQM+ are joining forces to demystify the intersection of MDR and the AI Act.
Speaker bios:
Chris A. Parr, PMP – Principal Consultant on Regulatory Affairs at RQM+
Chris Parr is a seasoned regulatory leader with 20+ years in the MedTech and pharmaceutical sectors. With a background in natural sciences, he offers deep expertise in regulatory affairs, quality management systems, risk management, design controls, and project management. He has led global teams, delivered complex projects in both industry and consulting, and is highly skilled in implementing the EU MDR and other EU legislation. Chris has worked directly with major regulatory bodies, including the US FDA, Health Canada, EU Competent Authorities, and Notified Bodies.
Dr. Andrei Ninu – Head of Software Operations at DQS
Andrei Ninu is a top-performing Product R&D professional with 15+ years of experience driving innovative, revenue-generating solutions in biomedical engineering. He has led products through the full lifecycle—from concept and prototyping to manufacturing, installation, and final commissioning—while excelling in research, clinical and feasibility studies, and process improvement. Andrei combines technical expertise with strong business acumen, conducting cost analyses, evaluating market segments, and shaping effective business and marketing strategies.
Certificate of attendance available upon request for live attendees.
RSVP for the Event 🡇
Fields marked with * are required.
